UGT1A4: A Drug Target / Disease Biomarker (G54657)

Target Name: UGT1A4

NCBI ID: G54657

UGT1A4

UGT1A4: A Drug Target / Disease Biomarker

UGT1A4 is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. The gene is located on chromosome 16 and has been shown to play a role in the development and progression of several diseases.

One of the most promising aspects of UGT1A4 is its potential as a drug target. The gene has been shown to be involved in the production of certain proteins that have been linked to the development of cancer, including breast, ovarian, and prostate cancers. Additionally, the gene has also been associated with the production of neurodegenerative proteins, which have been linked to the development of conditions such as Alzheimer's and Parkinson's disease.

In addition to its potential as a drug target, UGT1A4 has also been shown to be a potential biomarker for several diseases. The gene has been shown to be expressed in a variety of tissues and fluids, including blood, saliva, urine, and tissue samples from cancer patients. Additionally, the gene has been shown to be expressed in the brains of individuals with Alzheimer's and Parkinson's disease, providing a potential marker for the disease.

The potential uses of UGT1A4 as a drug target or biomarker make it an attractive target for researchers to study. If successful, a drug that targets UGT1A4 could be used to treat a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Additionally, the study of UGT1A4 as a biomarker could be used to diagnose and monitor the progression of these diseases.

While the potential uses of UGT1A4 are still in the early stages of research, it is clear that this gene has the potential to be a valuable tool for the study of disease and the development of new treatments. As research continues to progress, it is likely that we will learn more about the role of UGT1A4 in the development and progression of disease, and the potential uses of this gene as a drug target or biomarker will continue to grow.

Overall, UGT1A4 is a gene that has the potential to be a valuable tool for the study of disease and the development of new treatments. Through its role in the production of proteins linked to cancer and neurodegenerative disorders, as well as its potential as a drug target or biomarker, UGT1A4 has the potential to make a significant impact on the treatment of these diseases. As research continues to progress, it is likely that we will see new and exciting developments in the use of UGT1A4 as a tool for the study of disease and the development of new treatments.

Protein Name: UDP Glucuronosyltransferase Family 1 Member A4

Functions: UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:18177842, PubMed:24641623). Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds (PubMed:18177842). Involved in the glucuronidation of calcidiol, which is the major circulating form of vitamin D3 essential for the regulation of calcium and phosphate homeostasis (PubMed:24641623). Also glucuronidates the biologically active form of vitamin D3, calcitriol, probably leading to its biliary transport and intestinal reabsorption (PubMed:18177842)

The "UGT1A4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGT1A4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets